Follow-up
Further Inpatient Care
- Inpatient care is based on individual organ-system involvement.
- In general, no further care is needed.
Further Outpatient Care
- As disease activity subsides, taper medications to the lowest dose that effectively controls the symptoms and disease activity.
Inpatient & Outpatient Medications
- Inpatient and outpatient medication are the same (see Medication). All agents discussed above have been found to be effective in controlling the manifestations of Behçet disease.
Transfer
- Individualize the transfer situation for each patient based on the specifics of organ-system involvement.
Deterrence/Prevention
- Continual use of immunosuppressive medications may be required to suppress disease. Use the lowest dose required to control the manifestations of illness.
Complications
- Aneurysms are especially feared.
- Thrombotic events and vasculitis may lead to ischemia distal to vascular lesions.
- Uncontrolled ophthalmologic involvement in the form of anterior and posterior uveitis can lead to vision loss.
- Neurologic involvement suggests progressive disease and can lead to permanent deficits or even death.
Prognosis
- Prognosis is related to the site and severity of involvement.
Patient Education
- For excellent patient education resources, visit eMedicine Arthritis Center, Eye and Vision Center, and Teeth and Mouth Center. Also, see eMedicine patient education articles Canker Sores, Inflammatory Bowel Disease, and Iritis.
Miscellaneous
Medicolegal Pitfalls
- Adverse effects of medication
- Risk of misdiagnosis or failure to ascertain the extent of organ involvement
More on Behcet Disease |
| Overview: Behcet Disease |
| Differential Diagnoses & Workup: Behcet Disease |
| Treatment & Medication: Behcet Disease |
Follow-up: Behcet Disease |
| Multimedia: Behcet Disease |
| References |
| « Previous Page | Next Page » |
References
Adamantiades B. A case of recurrent hypopyon iritis. Medical Society of Athens. 1930;586-93.
International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. May 5 1990;335(8697):1078-80. [Medline].
Emmi L, Brugnolo F, Salvati G, et al. Immunopathological aspects of Behçet's disease. Clin Exp Rheumatol. Nov-Dec 1995;13(6):687-91. [Medline].
Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, et al. Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan. Clin Exp Immunol. May 1997;108(2):204-12. [Medline].
Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease. Lancet. Mar 23 1996;347(9004):789-94. [Medline].
Direskeneli H, Eksioglu-Demiralp E, Yavuz S, Ergun T, Shinnick T, Lehner T, et al. T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behçet's disease. J Rheumatol. Mar 2000;27(3):708-13. [Medline].
Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. Sep 1999;42(9):1967-74. [Medline].
Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci. May 1998;39(6):996-1004. [Medline].
Hallett MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today. Jun 1995;16(6):264-8. [Medline].
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. Oct 21 1999;341(17):1284-91. [Medline].
Sakane T, Suzuki N, Takeno M. Innate and acquired immunity in Behçet's disease. 8th International Congress on Behçet's Disease. Reggio Emilia, Italy, 7-9 October 1998. Program and Abstracts: 56.
Takeno M, Shimayano Y, Suzuki N, Sakane T. Prolonged survival of autoprimed neutrophils from patients with Behçet 's disease.: 8th International Congress on Behçet's Disease. Reggio Emilia, Italy, 7-9 October 1998. Program and Abstracts: 57.
Krause I, Yankevich A, Fraser A, Rosner I, Mader R, Zisman D, et al. Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol. Apr 2007;26(4):555-60. [Medline].
Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. Nov 1999;122 ( Pt 11):2171-82. [Medline].
Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J. Aug 31 2007;48(4):573-85. [Medline].
Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet disease. Curr Opin Rheumatol. Jan 2005;17(1):1-8. [Medline].
Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol. Sep 2007;42(9):737-45. [Medline].
Hemmen T, Perez-Canto A, Distler A, et al. IgA nephropathy in a patient with Behçet's syndrome--case report and review of literature. Br J Rheumatol. Jun 1997;36(6):696-9. [Medline].
Hashimoto T, Toya Y, Kihara M, Yabana M, Inayama Y, Tanaka K, et al. Behçet's disease complicated by IgA nephropathy with nephrotic syndrome. Clin Exp Nephrol. Jun 2008;12(3):224-7. [Medline].
[Best Evidence] Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A, et al. Cerebral venous thrombosis in Behçet's disease. Arthritis Rheum. Apr 15 2009;61(4):518-26. [Medline].
Kiraz S, Ertenli I, Oztürk MA, et al. Pathological haemostasis and "prothrombotic state" in Behçet's disease. Thromb Res. Jan 15 2002;105(2):125-33. [Medline].
Aktulga E, Altac M, Muftüoglu A, et al. A double blind study of colchicine in Behçet's disease. Haematologica. Jun 1980;65(3):399-402. [Medline].
Calis M, Ates F, Yazici C, Kose K, Kirnap M, Demir M, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease. Rheumatol Int. Aug 2005;25(6):452-6. [Medline].
Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). Oct 2002;41(10):1213-4. [Medline].
Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al. Seven-year follow-up of neurologic involvement in Behcet syndrome. Arch Neurol. Jul 1996;53(7):691-4. [Medline].
Akpolat T, Akkoyunlu M, Akpolat I, et al. Renal Behçet's disease: a cumulative analysis. Semin Arthritis Rheum. Apr 2002;31(5):317-37. [Medline].
Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry. May 2003;74(5):608-13. [Medline].
al-Dalaan A, al-Balla S, al-Sukait M. The Prevalence of Behcet's Disease in Al Qassim Region of Saudi Arabia. Revue du Rhumatisme (English). 1996;63:539.
al-Dalaan A, al-Sedairy S, al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease. J Rheumatol. May 1995;22(5):904-7. [Medline].
Behcet H. Uber rezidiverendeaphthose durch ein virus verursachte Geschwure am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr. 1937;105:1152-7.
Benamour S, Zeroual B, Bettal S. Digestive manifestations of Behcet's disease based on a series of 74 cases. In: Godeau P, Wechsler B, eds. Behcet's Disease. New York, NY: Elsevier Science; 1993:255-60.
Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet disease. A review. Neurologist. Mar 2005;11(2):80-9. [Medline].
Brama I, Fainaru M. Inner ear involvement in Behcet's disease. Arch Otolaryngol. Apr 1980;106(4):215-7. [Medline].
Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. Nov 2001;60(11):996-1002. [Medline].
Goker B, Goker H. Current therapy for Behçet's disease. Am J Ther. Sep-Oct 2002;9(5):465-70. [Medline].
Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs. 2007;67(14):2013-22. [Medline].
Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol. Jun 1994;21(6):1098-100. [Medline].
Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. Apr 1997;40(4):769-74. [Medline].
Hamuryudan V, Yurdakul S, Kural AR, et al. Diffuse proliferative glomerulonephritis in Behçet's syndrome. Br J Rheumatol. Feb 1991;30(1):63-4. [Medline].
Hazleman BL. Rheumatic disorders of the eye and the various structures involved. Br J Rheumatol. Mar 1996;35(3):258-68. [Medline].
Houman MH, Hamzaoui K. Promising new therapies for Behcet's disease. Eur J Intern Med. May 2006;17(3):163-9. [Medline].
Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's Disease. Semin Arthritis Rheum. Feb 1998;27(4):197-217. [Medline].
Kastner DL. Intermittent and Periodic Arthritic Syndromes: Behcet's Disease. In: Koopman WJ, ed. Arthritis and Allied Conditions. 13th ed. Baltimore, Md: Williams & Wilkins Co; 1997:1291-7.
Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). Jan 2003;82(1):60-76. [Medline].
Kötter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. Apr 2004;33(5):320-35. [Medline].
Larsson H. Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217). J Intern Med. Oct 1990;228(4):405-7. [Medline].
Marquardt JL, Snyderman R, Oppenheim JJ. Depression of lymphocyte transformation and exacerbation of Behcet's syndrome by ingestion of english walnuts. Cell Immunol. Nov 1973;9(2):263-72. [Medline].
O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am. May 1990;16(2):423-31. [Medline].
Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. Apr 1992;76(4):241-3. [Medline].
Ronco P, Wechsler B, Saillant G, Godeau P. [Aseptic osteonecrosis during corticosteroid treatment of Behçet's disease (author's transl)]. Nouv Presse Med. May 9 1981;10(21):1707-10. [Medline].
Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. Mar 2002;61(3):283-4. [Medline].
Schiff S, Moffatt R, Mandel WJ, et al. Acute myocardial infarction and recurrent ventricular arrhythmias in Behcet's syndrome. Am Heart J. Mar 1982;103(3):438-40. [Medline].
Seaman G, Pearce RA. Disease Manifestation in a population drawn from the U.K. Behcet's Syndrome Society. Revue du Rhumatisme (English). 1996;63:539.
Serdaroglu P, Yazici H, Ozdemir C, et al. Neurologic involvement in Behçet's syndrome. A prospective study. Arch Neurol. Mar 1989;46(3):265-9. [Medline].
Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. Nov 2002;61 Suppl 2:ii51-3. [Medline].
Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford). May 2007;46(5):736-41. [Medline].
Shahram F, Davatchi F, Akbarian M. The 1996 Survey of Behcet's disease in Iran, study of 3153 cases. Revue du Rhumatisme (English). 1996;63:538.
Shimizu T, Ehrlich GE, Inaba G, et al. Behçet disease (Behçet syndrome). Semin Arthritis Rheum. May 1979;8(4):223-60. [Medline].
Stratigos AJ, Laskaris G, Stratigos JD. Behcet's disease. Semin Neurol. Dec 1992;12(4):346-57. [Medline].
Suzuki N, Kaneko S, Ichino M, et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. Arthritis Rheum. Jun 1997;40(6):1157-67. [Medline].
Suzuki Y, Hoshi K, Matsuda T, et al. Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet's disease. J Rheumatol. Apr 1992;19(4):588-92. [Medline].
Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs. Apr 2005;17(2):97-107. [Medline].
Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. Jan 1997;24(1):128-32. [Medline].
van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis. Apr 2007;66(4):565-6. [Medline].
Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. Feb 1 1990;322(5):281-5. [Medline].
Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis. Dec 1984;43(6):783-9. [Medline].
Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol. Jan 2004;16(1):38-42. [Medline].
Zouboulis CC, Diawari D, Kirch W. Adamantiades-Behcet's disease in Germany: Data of the German registry in 1996. Revue du Rhumatisme (English). 1996;63:538.
Further Reading
Keywords
Behçet disease, Behcet disease, Behçet syndrome, Behcet syndrome, Behçet's disease, Adamantiades-Behçet disease, BD, inflammatory arthritis, sacroiliitis, ulcerative lesions, aphthous ulcers, oral ulcers, oral lesions, skin lesions, genital ulcers, phlebitis, uveitis, iritis, hypopyon, retinal vasculitis, erythema nodosum, pseudofolliculitis, papulopustular lesions, pathergy, vasculopathy, superficial thrombophlebitis, deep venous thrombophlebitis, Budd-Chiari syndrome, mouth and genital ulcers with inflamed cartilage, MAGIC, autoimmune disease
Follow-up: Behcet Disease